Abstract Details

Title Clinical Characteristics of COVID-19 in Patients with Parkinson’s Disease

Topic Movement Disorders

Presentation(s) P1 - Poster Session 1 (8:00 AM-9:00 AM)

Poster/Presentation
Number 5-008

Objective

Describe clinical characteristics of COVID-19 in patients with Parkinson’s disease (PD).

Background

Individuals with PD have an increased risk of severe illness and poor outcomes in the context of COVID-19, though more research is needed.

Design/Methods

We retrospectively analyzed clinical data from 18 consecutive patients with PD and COVID-19 presenting to a suburban hospital in the Northwest United States.

Results Our sample was predominantly male (61%) with a mean age of 71. The most common presenting symptoms of COVID-19 were cough (72%), fever (61%), and shortness of breath (50%). The most common comorbid conditions were hypertension (50%), obstructive sleep apnea (33%), dementia (33%), cardiovascular disease (22%), diabetes mellitus (22%), and lung disease (11%). Two patients (11%) had a history of deep brain stimulation, one of whom was also on an apomorphine pump trial. Two patients were asymptomatic with one testing positive on routine screening following an outbreak at her residential facility and the other testing positive prior to a sleep study. The latter received monoclonal antibody infusion as part of FDA emergency use authorization. Six patients (33%) required hospitalization. Eight patients (44%) had exacerbation of underlying PD symptomology. Five of six patients with PD dementia presented with encephalopathy. Two patients presented with increased tremor, one with increased lightheadedness, and one with increased falls. Two patients died. Both deceased patients had PD dementia and presented with encephalopathy.

Conclusions

In this cohort of 18 patients with PD and COVID-19, 44% experienced exacerbation of PD symptomology including encephalopathy in those with dementia, tremor, lightheadedness, and falls. Both mortalities were associated with baseline dementia and encephalopathy as a presenting symptom. The results of our study further highlight the risk of severe illness and poor outcomes in those with PD and COVID-19. These findings will be helpful for treating physicians, researchers, individuals with PD and their carepartners.

Authors/Disclosures
PRESENTER	No disclosure on file
	No disclosure on file
Pinky Agarwal, MD, FAAN (Evergreen Health)	Dr. Agarwal has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Supernus. Dr. Agarwal has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Acadia Pharmaceuticals Inc. Dr. Agarwal has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Amneal. Dr. Agarwal has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Neurocrine. Dr. Agarwal has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Mitsubishi Tanabe Pharma. Dr. Agarwal has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for AbbVie. Dr. Agarwal has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Avion Pharmaceuticals. Dr. Agarwal has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Acadia. Dr. Agarwal has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Supernus. Dr. Agarwal has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Kyowa Kirin. Dr. Agarwal has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Amneal. Dr. Agarwal has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for AbbVie. Dr. Agarwal has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Neurocrine. Dr. Agarwal has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for AskBio. An immediate family member of Dr. Agarwal has stock in ALDEYRA THERAPEUTICS INC. An immediate family member of Dr. Agarwal has stock in Curis Inc. An immediate family member of Dr. Agarwal has stock in Citius Pharmaceuticals. An immediate family member of Dr. Agarwal has stock in Fortress Biotech. An immediate family member of Dr. Agarwal has stock in TG Therapeutics. An immediate family member of Dr. Agarwal has stock in ATYR PHARMA INC . An immediate family member of Dr. Agarwal has stock in CORVUS PHARMACEUTICALS INC . An immediate family member of Dr. Agarwal has stock in LAVA THERAPEUTICS . An immediate family member of Dr. Agarwal has stock in OVID THERAPEUTICS INC . An immediate family member of Dr. Agarwal has stock in TERNS PHARMACEUTICALS INC. An immediate family member of Dr. Agarwal has stock in VIKING THERAPEUTICS INC. Dr. Agarwal has stock in WAVE LIFE SCIENCES LTD. An immediate family member of Dr. Agarwal has stock in ProQr Therapeutics. An immediate family member of Dr. Agarwal has stock in Mind Medicine. An immediate family member of Dr. Agarwal has stock in Lyra Therapeutics. An immediate family member of Dr. Agarwal has stock in Larimer Therapeutics. An immediate family member of Dr. Agarwal has stock in Lantern Pharma. An immediate family member of Dr. Agarwal has stock in Black Diamond Therapeutics. An immediate family member of Dr. Agarwal has stock in Amylyx Pharma. An immediate family member of Dr. Agarwal has stock in Palisade Bio. An immediate family member of Dr. Agarwal has stock in Inozyme Pharma. An immediate family member of Dr. Agarwal has stock in Pyxis Oncology. An immediate family member of Dr. Agarwal has stock in Vertex Pharmaceuticals. An immediate family member of Dr. Agarwal has stock in Vyne Therapeutics. An immediate family member of Dr. Agarwal has stock in Reviva Pharmaceuticals Hld. An immediate family member of Dr. Agarwal has stock in Immuneering Corp. An immediate family member of Dr. Agarwal has stock in Imunon Inc. An immediate family member of Dr. Agarwal has stock in Enlivex Therapeutics. An immediate family member of Dr. Agarwal has stock in Candel Therapeutics. An immediate family member of Dr. Agarwal has stock in Applied Digital Corp. An immediate family member of Dr. Agarwal has stock in Atai Life Sciences. An immediate family member of Dr. Agarwal has stock in Adma Biologics. The institution of Dr. Agarwal has received research support from Biogen . The institution of Dr. Agarwal has received research support from CHDI Foundation. The institution of Dr. Agarwal has received research support from Eli Lilly. The institution of Dr. Agarwal has received research support from MJ Fox. The institution of Dr. Agarwal has received research support from Roche . The institution of Dr. Agarwal has received research support from Supernus. The institution of Dr. Agarwal has received research support from Nova Nordisc. The institution of Dr. Agarwal has received research support from Inhibikase. The institution of Dr. Agarwal has received research support from Intracellular therapeurtics.

��ɫ��

��ɫ��